Latest Headlines

Latest Headlines

BMS, Roche join forces and drugs on combo melanoma program

If you want to attack an aggressive killer like metastatic melanoma, it's best to target it from as many angles as possible. That's the approach that Roche is taking with its promising late-stage

Roche cancer programs angle for a starring role at ASCO

Roche set the stage for its upcoming review of new mid- and late-stage data on vemurafenib--its closely watched experimental treatment for skin cancer licensed in from Plexxikon-at the annual ASCO

Roche, Plexxikon melanoma drug extends patients' lives

Roche and partner Plexxikon have reported a rare success in the challenging field of melanoma. Closely-watched drug PLX4032 extended the lives of subjects with metastatic melanoma in a Phase III

PLX4032 inspires fierce debate over cancer trial designs

Plexxikon's PLX4032 has been the subject of tremendous buzz after the biotech unveiled startling efficacy data from a small trial of lethal melanoma cases. Now its pivotal study is triggering a loud

Roche melanoma drug registers striking results

An experimental personalized cancer therapy from Roche and Plexxikon registered striking results in a recent clinical study, shrinking the tumors in a majority of metastatic melanoma patients who

The roller coaster ride of melanoma drug development

This week, the New York Times is tracing the Phase I testing of a novel melanoma drug being developed by Plexxikon and Roche. The paper says to chronicle the three years of PLX4032 testing "is to